查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2154604

mRNA疫苗原料市場：全球市場預測，2026-2032年

mRNA Vaccine Raw Materials Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，mRNA 疫苗原料市場將成長至 72.5 億美元，複合年成長率為 12.47%。

主要市場統計數據
基準年 2025 31.8億美元
預計年份：2026年 35.6億美元
預測年份 2032 72.5億美元
複合年成長率 (%) 12.47%

mRNA疫苗原料概述

mRNA疫苗的原料包括核苷、核苷酸、脂質、酵素、質體DNA、緩衝液、過濾材料和一次性生產組件。其策略重要性取決於能否保障產品品質、供應連續性、符合法規要求、以及實現快速、可重複的生產。因此，要了解這個市場，不僅要關注供應量，還要關注平台準備及其在生物製藥韌性中的作用。

供應韌性正在重塑原料策略。

產業趨勢正從狹隘的最佳化採購轉向多元化、合格且可追溯的供應鏈網路。製造商更重視雙重採購、區域生產能力、檢驗的替代品、冷鏈可靠性以及早期品質協議。監管機構對產品一致性、雜質控制、無菌保證和變更控制記錄的要求也在不斷提高，這進一步凸顯了供應商合格和全生命週期監管的重要性。

人工智慧可以提高品質和營運決策水準。

人工智慧 (AI) 可以改善 mRNA 原料生產整體的需求預測、批次記錄審核、偏差優先排序、庫存優先排序和程式參數分析。當 AI 與實驗室資訊、企業資源計劃 (ERP) 和生產數據相結合時，其價值將顯著提升。然而，AI 的實施仍需要檢驗的模型、資料管治、網路安全措施、人工審核和明確的責任機制，尤其是在演算法輸出可能影響產品發布、供應商核准或製程變更的情況下。

區域趨勢反映了製造業優先事項的差異。

在北美，先進的生物製造基礎設施與對國內韌性和監管管理的重視相結合。在歐洲，重點在於統一的品質系統、永續性和協調的跨境供應鏈的穩定性。在亞太地區，核酸製造、脂質化學和合約開發能力正在不斷擴展，同時滿足多樣化的國內和出口需求。拉丁美洲專注於技術取得、本地生產能力和可靠的進口管道。在中東，投資重點放在生命科學基礎設施和戰略製造夥伴關係關係上，而非洲的優先事項包括技術取得、技術轉移、人力資源開發和可靠的分銷。

多邊組織塑造標準、准入和韌性。

東南亞國協正加強區域醫藥合作，同時努力解決監管成熟度和生產能力的差距。金磚國家在科學、工業和公共衛生領域擁有相當的實力，但在標準制定和跨境供應方面需要採取協調一致的方法。歐盟支持通用的法規結構和戰略自主計劃。七國集團正在影響先進的研發、品質預期和韌性政策。海灣合作理事會國家正在建構醫療衛生和製造業生態系統，而北約成員國則更重視戰備、安全物流和關鍵物資的持續供應。

每個國家的能力各不相同，從平台領先國家到新興生產國家都有。

美國、加拿大、英國、英國、法國、義大利、西班牙、日本、韓國、中國、印度和澳洲各自具備研發、生產、監管和醫療保健方面的能力，並在脂質、核酸化學、填充和包裝、分析測試以及供應鏈管理方面各有優勢。巴西和墨西哥是拉丁美洲重要的生產和分銷中心。俄羅斯保持其科學研究和製藥能力，但在貿易、技術取得和供應鏈整合方面面臨許多限制。國家層級的準備取決於基礎設施、熟練人員、監管協調以及合格原料的取得。

優先考慮資格確認、冗餘和資料驅動管理。

產業領導者應將關鍵原料分配給認證供應商，識別潛在故障點，並在短缺發生前製定基於風險的替代方案。長期品質合約應明確規定規格、通知期限、審核權限、測試責任和變更控管程序。企業還應投資於區域製造夥伴關係、健全的庫存管理政策、供應商網路安全以及分析可比性計劃。人工智慧 (AI) 的實施應透過受控用例、經過檢驗的數據、有記錄的人工監督以及可衡量的品質和服務結果來進行。

調查方法：基於證據的供應鏈生態系評估

本執行摘要採用結構化的定性評估方法，對mRNA疫苗原料生態系進行分析。分析內容包括原料分類、生產依賴性、品質和監管要求、供應鏈韌性、技術應用、區域狀況、集團層面的合作以及國家能力。研究結果圍繞著可觀察到的產業促進因素和限制因素進行總結，不提供市場估算或預測。區域比較反映了基礎設施、政策、科學基礎和取得條件的差異。

充足的原料供應對於mRNA平台的就緒至關重要。

mRNA疫苗原料的策略重點在於建立可靠、合規且適應性強的供應鏈。能夠整合多元化供應商、嚴格品管系統、跨區域合作、透明可追溯性以及精心管理的人工智慧技術的組織，將更有能力支援快速的生產回應。進展不僅取決於化學技術和生產能力，還取決於協調一致的監管、高技能的勞動力、安全的物流以及對具有韌性的生物製藥生態系統的持續投資。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 mRNA疫苗原料市場：依原料類型分類

  • 緩衝溶液
    • HEPES
    • 磷酸鹽緩衝液
    • Tris緩衝溶液
  • 加帽酶
  • 脂質
    • 膽固醇
    • 可電離脂質
    • 聚乙二醇化脂質
    • 結構脂質
  • 核苷三磷酸
    • ATP
    • CTP
    • GTP
    • UTP
  • 純化樹脂
    • 親和性
    • 離子交換
  • 鹽試劑
    • 氯化鉀
    • 氯化鈉
  • 溶劑
    • 乙醇
    • 異丙醇

第8章 mRNA疫苗原料市場：依遞送系統分類

  • 基於外泌體的
    • 修飾的外泌體
    • 天然來源的外吐小體
  • 脂質奈米顆粒
    • 可電離脂質顆粒
    • 聚乙二醇化脂質顆粒
  • 基於胜肽的
    • 細胞穿透胜肽
    • 融合誘導胜肽
  • 聚合物奈米粒子
    • 幾丁聚醣顆粒
    • PLGA顆粒

第9章：mRNA疫苗原料市場：依製程階段分類

  • 封頂
  • 填充和精加工
  • 配方
  • 純化
  • 合成

第10章：mRNA疫苗原料市場：依應用領域分類

  • 感染疾病
    • 2019冠狀病毒病疫苗
    • 流感疫苗
  • 腫瘤學
    • 血液疾病疫苗
    • 固體癌疫苗

第11章：mRNA疫苗原料市場：依最終用途分類

  • 人用疫苗
  • 動物疫苗

第12章 mRNA疫苗原料市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：mRNA疫苗原料市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 mRNA疫苗原料市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AGC Inc.
  • BioNTech SE
  • Catalent, Inc.
  • CureVac NV
  • Cytiva Life Sciences
  • Danaher Corporation
  • FUJIFILM Holdings Corporation
  • Ginkgo Bioworks Holdings, Inc.
  • Lonza Group AG
  • Maravai LifeSciences Holdings, Inc.
  • Merck KGaA
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Repligen Corporation
  • Sanofi SA
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • TriLink BioTechnologies
  • WuXi Biologics Inc.

第17章 主要專家

Product Code: MRR-537DB9F46E5C

The mRNA Vaccine Raw Materials Market is projected to grow by USD 7.25 billion at a CAGR of 12.47% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.18 billion
Estimated Year [2026] USD 3.56 billion
Forecast Year [2032] USD 7.25 billion
CAGR (%) 12.47%

mRNA Vaccine Raw Materials: Executive Overview

mRNA vaccine raw materials encompass nucleosides, nucleotides, lipids, enzymes, plasmid DNA, buffers, filtration inputs, and single-use manufacturing components. Their strategic importance is shaped by product quality, supply continuity, regulatory compliance, and the ability to support rapid, reproducible manufacturing. The market is therefore best understood through its role in platform readiness and biopharmaceutical resilience rather than through volume alone.

Supply Resilience Is Reshaping Raw-Material Strategy

The landscape is shifting from narrowly optimized procurement toward diversified, qualified, and traceable supply networks. Manufacturers are placing greater emphasis on dual sourcing, regional production capabilities, validated alternatives, cold-chain reliability, and early quality agreements. Regulatory expectations for consistency, impurity control, sterility assurance, and documented change management are also increasing the importance of supplier qualification and lifecycle oversight.

Artificial Intelligence Strengthens Quality and Operational Decisions

Artificial intelligence can improve demand sensing, batch-record review, deviation triage, inventory prioritization, and process-parameter analysis across mRNA raw-material operations. Its value is cumulative when combined with laboratory information, enterprise resource planning, and manufacturing data. Adoption still requires validated models, data governance, cybersecurity controls, human review, and clear accountability, particularly where algorithmic outputs could influence release, supplier approval, or process changes.

Regional Dynamics Reflect Different Manufacturing Priorities

North America combines advanced biomanufacturing infrastructure with strong attention to domestic resilience and regulatory control. Europe emphasizes harmonized quality systems, sustainability, and coordinated supply security across national borders. Asia-Pacific is expanding capabilities in nucleic-acid manufacturing, lipid chemistry, and contract development while serving diverse domestic and export needs. Latin America is focused on technology access, local production capacity, and dependable import channels. The Middle East is investing in life-science infrastructure and strategic manufacturing partnerships, while Africa's priorities include access, technology transfer, workforce development, and reliable distribution.

Multilateral Groups Shape Standards, Access, and Resilience

ASEAN economies are strengthening regional pharmaceutical cooperation while addressing varied regulatory maturity and manufacturing capacity. BRICS members bring substantial scientific, industrial, and public-health capabilities but require coordinated approaches to standards and cross-border supply. The European Union supports common regulatory structures and strategic autonomy initiatives. G7 countries influence advanced research, quality expectations, and resilience policy. GCC states are developing healthcare and manufacturing ecosystems, whereas NATO members place additional emphasis on preparedness, secure logistics, and continuity of critical supplies.

Country Capabilities Range from Platform Leaders to Emerging Producers

The United States, Canada, the United Kingdom, Germany, France, Italy, Spain, Japan, South Korea, China, India, and Australia each contribute combinations of research, manufacturing, regulation, and healthcare capacity, with differing strengths in lipid systems, nucleic-acid chemistry, fill-finish, analytical testing, and supply-chain management. Brazil and Mexico are important Latin American manufacturing and distribution hubs. Russia retains scientific and pharmaceutical capabilities but faces constraints linked to trade, technology access, and supply-chain integration. Country-level readiness depends on infrastructure, skilled personnel, regulatory alignment, and access to qualified inputs.

Prioritize Qualification, Redundancy, and Data-Enabled Control

Industry leaders should map critical raw materials to qualified suppliers, identify single points of failure, and establish risk-based alternatives before shortages occur. Long-term quality agreements should define specifications, notification periods, audit rights, testing responsibilities, and change-control procedures. Organizations should also invest in regional manufacturing partnerships, robust inventory policies, supplier cybersecurity, and analytical comparability programs. Artificial intelligence should be introduced through controlled use cases with validated data, documented human oversight, and measurable quality and service outcomes.

Methodology: Evidence-Based Assessment of the Supply Ecosystem

This executive summary uses a structured qualitative assessment of the mRNA vaccine raw-material ecosystem. The analysis considers material categories, manufacturing dependencies, quality and regulatory requirements, supply-chain resilience, technology adoption, regional conditions, group-level cooperation, and country capabilities. Findings are framed around observable industry drivers and constraints, without presenting market estimates, market sizing, market shares, or forecasts. Geographic comparisons reflect differences in infrastructure, policy, scientific capacity, and access conditions.

Resilient Inputs Will Define mRNA Platform Readiness

The strategic priority for mRNA vaccine raw materials is dependable, compliant, and adaptable supply. Organizations that combine supplier diversification, rigorous quality systems, regional collaboration, transparent traceability, and carefully governed artificial intelligence will be better positioned to support rapid manufacturing response. Progress will depend not only on chemistry and production capacity, but also on coordinated regulation, skilled workforces, secure logistics, and sustained investment in resilient biopharmaceutical ecosystems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. mRNA Vaccine Raw Materials Market, by Material Type

  • 7.1. Introduction
  • 7.2. Buffers
    • 7.2.1. Hepes
    • 7.2.2. Phosphate Buffer
    • 7.2.3. Tris Buffer
  • 7.3. Capping Enzymes
  • 7.4. Lipids
    • 7.4.1. Cholesterol
    • 7.4.2. Ionizable Lipids
    • 7.4.3. Pegylated Lipids
    • 7.4.4. Structural Lipids
  • 7.5. Nucleotide Triphosphates
    • 7.5.1. ATP
    • 7.5.2. CTP
    • 7.5.3. GTP
    • 7.5.4. UTP
  • 7.6. Purification Resins
    • 7.6.1. Affinity
    • 7.6.2. Ion Exchange
  • 7.7. Salt Reagents
    • 7.7.1. Potassium Chloride
    • 7.7.2. Sodium Chloride
  • 7.8. Solvents
    • 7.8.1. Ethanol
    • 7.8.2. Isopropanol

8. mRNA Vaccine Raw Materials Market, by Delivery System

  • 8.1. Introduction
  • 8.2. Exosome Based
    • 8.2.1. Engineered Exosomes
    • 8.2.2. Natural Exosomes
  • 8.3. Lipid Nanoparticles
    • 8.3.1. Ionizable Lipid Particles
    • 8.3.2. Pegylated Lipid Particles
  • 8.4. Peptide Based
    • 8.4.1. Cell Penetrating Peptides
    • 8.4.2. Fusogenic Peptides
  • 8.5. Polymeric Nanoparticles
    • 8.5.1. Chitosan Particles
    • 8.5.2. PLGA Particles

9. mRNA Vaccine Raw Materials Market, by Process Stage

  • 9.1. Introduction
  • 9.2. Capping
  • 9.3. Filling And Finishing
  • 9.4. Formulation
  • 9.5. Purification
  • 9.6. Synthesis

10. mRNA Vaccine Raw Materials Market, by Application

  • 10.1. Introduction
  • 10.2. Infectious Diseases
    • 10.2.1. COVID-19 Vaccines
    • 10.2.2. Influenza Vaccines
  • 10.3. Oncology
    • 10.3.1. Hematologic Vaccine
    • 10.3.2. Solid Tumor Vaccines

11. mRNA Vaccine Raw Materials Market, by End Use

  • 11.1. Introduction
  • 11.2. Human Vaccines
  • 11.3. Veterinary Vaccines

12. mRNA Vaccine Raw Materials Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. mRNA Vaccine Raw Materials Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. mRNA Vaccine Raw Materials Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AGC Inc.
  • 16.2. BioNTech SE
  • 16.3. Catalent, Inc.
  • 16.4. CureVac N.V.
  • 16.5. Cytiva Life Sciences
  • 16.6. Danaher Corporation
  • 16.7. FUJIFILM Holdings Corporation
  • 16.8. Ginkgo Bioworks Holdings, Inc.
  • 16.9. Lonza Group AG
  • 16.10. Maravai LifeSciences Holdings, Inc.
  • 16.11. Merck KGaA
  • 16.12. Moderna, Inc.
  • 16.13. Novartis AG
  • 16.14. Pfizer Inc.
  • 16.15. Repligen Corporation
  • 16.16. Sanofi S.A.
  • 16.17. Sartorius AG
  • 16.18. Thermo Fisher Scientific Inc.
  • 16.19. TriLink BioTechnologies
  • 16.20. WuXi Biologics Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global mRNA Vaccine Raw Materials Market, Years Considered for the Study
  • FIGURE 2. Global mRNA Vaccine Raw Materials Market, Research Design
  • FIGURE 3. Global mRNA Vaccine Raw Materials Market, Research Framework
  • FIGURE 4. Global mRNA Vaccine Raw Materials Market, Data Triangulation
  • FIGURE 5. Global mRNA Vaccine Raw Materials Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global mRNA Vaccine Raw Materials Market Size, by Material Type, 2025 vs 2032 (%)
  • FIGURE 7. Global mRNA Vaccine Raw Materials Market Size, by Material Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global mRNA Vaccine Raw Materials Market Size, by Delivery System, 2025 vs 2032 (%)
  • FIGURE 9. Global mRNA Vaccine Raw Materials Market Size, by Delivery System, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global mRNA Vaccine Raw Materials Market Size, by Process Stage, 2025 vs 2032 (%)
  • FIGURE 11. Global mRNA Vaccine Raw Materials Market Size, by Process Stage, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global mRNA Vaccine Raw Materials Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 13. Global mRNA Vaccine Raw Materials Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global mRNA Vaccine Raw Materials Market Size, by End Use, 2025 vs 2032 (%)
  • FIGURE 15. Global mRNA Vaccine Raw Materials Market Size, by End Use, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global mRNA Vaccine Raw Materials Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global mRNA Vaccine Raw Materials Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global mRNA Vaccine Raw Materials Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global mRNA Vaccine Raw Materials Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global mRNA Vaccine Raw Materials Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global mRNA Vaccine Raw Materials Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global mRNA Vaccine Raw Materials Market Segmentation & Coverage
  • TABLE 2. Global mRNA Vaccine Raw Materials Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 4. Global Buffers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Buffers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Buffers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Hepes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Hepes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Hepes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Phosphate Buffer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Phosphate Buffer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Phosphate Buffer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Tris Buffer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Tris Buffer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Tris Buffer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Capping Enzymes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Capping Enzymes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Capping Enzymes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Lipids Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Lipids Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Lipids Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Cholesterol Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Cholesterol Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Cholesterol Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Ionizable Lipids Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Ionizable Lipids Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Ionizable Lipids Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Pegylated Lipids Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Pegylated Lipids Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Pegylated Lipids Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Structural Lipids Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Structural Lipids Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Structural Lipids Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Nucleotide Triphosphates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Nucleotide Triphosphates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Nucleotide Triphosphates Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global ATP Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global ATP Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global ATP Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global CTP Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global CTP Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global CTP Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global GTP Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global GTP Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global GTP Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global UTP Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global UTP Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global UTP Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Purification Resins Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Purification Resins Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Purification Resins Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Affinity Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global Affinity Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global Affinity Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global Ion Exchange Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Ion Exchange Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Ion Exchange Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Salt Reagents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Salt Reagents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Salt Reagents Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Potassium Chloride Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Potassium Chloride Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Potassium Chloride Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Sodium Chloride Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Sodium Chloride Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Sodium Chloride Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Solvents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Solvents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Solvents Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Ethanol Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Ethanol Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Ethanol Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global Isopropanol Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Isopropanol Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Isopropanol Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 77. Global Exosome Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global Exosome Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global Exosome Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global Engineered Exosomes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Engineered Exosomes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Engineered Exosomes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global Natural Exosomes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global Natural Exosomes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global Natural Exosomes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global Lipid Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Global Lipid Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. Global Lipid Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 89. Global Ionizable Lipid Particles Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Global Ionizable Lipid Particles Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. Global Ionizable Lipid Particles Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 92. Global Pegylated Lipid Particles Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 93. Global Pegylated Lipid Particles Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 94. Global Pegylated Lipid Particles Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 95. Global Peptide Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. Global Peptide Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 97. Global Peptide Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 98. Global Cell Penetrating Peptides Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. Global Cell Penetrating Peptides Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 100. Global Cell Penetrating Peptides Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 101. Global Fusogenic Peptides Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. Global Fusogenic Peptides Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. Global Fusogenic Peptides Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 104. Global Polymeric Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. Global Polymeric Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 106. Global Polymeric Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 107. Global Chitosan Particles Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 108. Global Chitosan Particles Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. Global Chitosan Particles Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 110. Global PLGA Particles Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 111. Global PLGA Particles Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 112. Global PLGA Particles Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 113. Global mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 114. Global Capping Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 115. Global Capping Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. Global Capping Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 117. Global Filling And Finishing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 118. Global Filling And Finishing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 119. Global Filling And Finishing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 120. Global Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 121. Global Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 122. Global Formulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 123. Global Purification Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 124. Global Purification Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 125. Global Purification Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 126. Global Synthesis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 127. Global Synthesis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 128. Global Synthesis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 129. Global mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 130. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 131. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 132. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 133. Global COVID-19 Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 134. Global COVID-19 Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 135. Global COVID-19 Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 136. Global Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 137. Global Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 138. Global Influenza Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 139. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 140. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 141. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 142. Global Hematologic Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 143. Global Hematologic Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 144. Global Hematologic Vaccine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 145. Global Solid Tumor Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 146. Global Solid Tumor Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 147. Global Solid Tumor Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 148. Global mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
  • TABLE 149. Global Human Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 150. Global Human Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 151. Global Human Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 152. Global Veterinary Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 153. Global Veterinary Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 154. Global Veterinary Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 155. Global mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 156. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 157. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 158. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
  • TABLE 159. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
  • TABLE 160. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
  • TABLE 161. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
  • TABLE 162. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
  • TABLE 163. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
  • TABLE 164. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 165. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
  • TABLE 166. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
  • TABLE 167. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 168. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
  • TABLE 169. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 170. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 171. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 172. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 173. Asia-Pacific mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
  • TABLE 174. North America mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 175. North America mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 176. North America mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
  • TABLE 177. North America mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
  • TABLE 178. North America mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
  • TABLE 179. North America mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
  • TABLE 180. North America mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
  • TABLE 181. North America mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
  • TABLE 182. North America mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 183. North America mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
  • TABLE 184. North America mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
  • TABLE 185. North America mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 186. North America mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
  • TABLE 187. North America mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 188. North America mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 189. North America mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 190. North America mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 191. North America mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
  • TABLE 192. Latin America mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 193. Latin America mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 194. Latin America mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
  • TABLE 195. Latin America mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
  • TABLE 196. Latin America mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
  • TABLE 197. Latin America mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
  • TABLE 198. Latin America mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
  • TABLE 199. Latin America mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
  • TABLE 200. Latin America mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 201. Latin America mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
  • TABLE 202. Latin America mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
  • TABLE 203. Latin America mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 204. Latin America mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
  • TABLE 205. Latin America mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 206. Latin America mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 207. Latin America mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 208. Latin America mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 209. Latin America mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
  • TABLE 210. Europe mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 211. Europe mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 212. Europe mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
  • TABLE 213. Europe mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
  • TABLE 214. Europe mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
  • TABLE 215. Europe mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
  • TABLE 216. Europe mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
  • TABLE 217. Europe mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
  • TABLE 218. Europe mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 219. Europe mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
  • TABLE 220. Europe mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
  • TABLE 221. Europe mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 222. Europe mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
  • TABLE 223. Europe mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 224. Europe mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 225. Europe mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 226. Europe mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 227. Europe mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
  • TABLE 228. Middle East mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 229. Middle East mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 230. Middle East mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
  • TABLE 231. Middle East mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
  • TABLE 232. Middle East mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
  • TABLE 233. Middle East mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
  • TABLE 234. Middle East mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
  • TABLE 235. Middle East mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
  • TABLE 236. Middle East mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 237. Middle East mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
  • TABLE 238. Middle East mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
  • TABLE 239. Middle East mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 240. Middle East mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
  • TABLE 241. Middle East mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 242. Middle East mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 243. Middle East mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 244. Middle East mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 245. Middle East mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
  • TABLE 246. Africa mRNA Vaccine Raw Materials Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 247. Africa mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 248. Africa mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
  • TABLE 249. Africa mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
  • TABLE 250. Africa mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
  • TABLE 251. Africa mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
  • TABLE 252. Africa mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
  • TABLE 253. Africa mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
  • TABLE 254. Africa mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 255. Africa mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
  • TABLE 256. Africa mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
  • TABLE 257. Africa mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 258. Africa mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
  • TABLE 259. Africa mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 260. Africa mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 261. Africa mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 262. Africa mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 263. Africa mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
  • TABLE 264. Global mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 265. ASEAN mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 266. ASEAN mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 267. ASEAN mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
  • TABLE 268. ASEAN mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
  • TABLE 269. ASEAN mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
  • TABLE 270. ASEAN mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
  • TABLE 271. ASEAN mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
  • TABLE 272. ASEAN mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
  • TABLE 273. ASEAN mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 274. ASEAN mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
  • TABLE 275. ASEAN mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
  • TABLE 276. ASEAN mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 277. ASEAN mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
  • TABLE 278. ASEAN mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 279. ASEAN mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 280. ASEAN mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 281. ASEAN mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 282. ASEAN mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
  • TABLE 283. GCC mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 284. GCC mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 285. GCC mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
  • TABLE 286. GCC mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
  • TABLE 287. GCC mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
  • TABLE 288. GCC mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
  • TABLE 289. GCC mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
  • TABLE 290. GCC mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
  • TABLE 291. GCC mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 292. GCC mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
  • TABLE 293. GCC mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
  • TABLE 294. GCC mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 295. GCC mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
  • TABLE 296. GCC mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 297. GCC mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 298. GCC mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 299. GCC mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 300. GCC mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
  • TABLE 301. European Union mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 302. European Union mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 303. European Union mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
  • TABLE 304. European Union mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
  • TABLE 305. European Union mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
  • TABLE 306. European Union mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
  • TABLE 307. European Union mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
  • TABLE 308. European Union mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
  • TABLE 309. European Union mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 310. European Union mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
  • TABLE 311. European Union mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
  • TABLE 312. European Union mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 313. European Union mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
  • TABLE 314. European Union mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 315. European Union mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 316. European Union mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 317. European Union mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 318. European Union mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
  • TABLE 319. BRICS mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 320. BRICS mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 321. BRICS mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
  • TABLE 322. BRICS mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
  • TABLE 323. BRICS mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
  • TABLE 324. BRICS mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
  • TABLE 325. BRICS mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
  • TABLE 326. BRICS mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
  • TABLE 327. BRICS mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 328. BRICS mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
  • TABLE 329. BRICS mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
  • TABLE 330. BRICS mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 331. BRICS mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
  • TABLE 332. BRICS mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 333. BRICS mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 334. BRICS mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 335. BRICS mRNA Vaccine Raw Materials Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 336. BRICS mRNA Vaccine Raw Materials Market Size, by End Use, 2017-2032 (USD Million)
  • TABLE 337. G7 mRNA Vaccine Raw Materials Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 338. G7 mRNA Vaccine Raw Materials Market Size, by Material Type, 2017-2032 (USD Million)
  • TABLE 339. G7 mRNA Vaccine Raw Materials Market Size, by Buffers, 2017-2032 (USD Million)
  • TABLE 340. G7 mRNA Vaccine Raw Materials Market Size, by Lipids, 2017-2032 (USD Million)
  • TABLE 341. G7 mRNA Vaccine Raw Materials Market Size, by Nucleotide Triphosphates, 2017-2032 (USD Million)
  • TABLE 342. G7 mRNA Vaccine Raw Materials Market Size, by Purification Resins, 2017-2032 (USD Million)
  • TABLE 343. G7 mRNA Vaccine Raw Materials Market Size, by Salt Reagents, 2017-2032 (USD Million)
  • TABLE 344. G7 mRNA Vaccine Raw Materials Market Size, by Solvents, 2017-2032 (USD Million)
  • TABLE 345. G7 mRNA Vaccine Raw Materials Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 346. G7 mRNA Vaccine Raw Materials Market Size, by Exosome Based, 2017-2032 (USD Million)
  • TABLE 347. G7 mRNA Vaccine Raw Materials Market Size, by Lipid Nanoparticles, 2017-2032 (USD Million)
  • TABLE 348. G7 mRNA Vaccine Raw Materials Market Size, by Peptide Based, 2017-2032 (USD Million)
  • TABLE 349. G7 mRNA Vaccine Raw Materials Market Size, by Polymeric Nanoparticles, 2017-2032 (USD Million)
  • TABLE 350. G7 mRNA Vaccine Raw Materials Market Size, by Process Stage, 2017-2032 (USD Million)
  • TABLE 351. G7 mRNA Vaccine Raw Materials Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 352. G7 mRNA Vaccine Raw Materials Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 353. G7 mRNA Vaccine Raw Materials